RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018)
Gnanasakthy, A., Russo, J., Gnanasakthy, K., Harris, N., & Castro, C. (2022). A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemporary Clinical Trials, 120, 106860. https://doi.org/10.1016/j.cct.2022.106860
The Food and Drug Administration (FDA) encourages the assessment of patient-reported outcomes (PROs) in oncology clinical trials. A 2015 review showed that approximately 26% of industry-sponsored oncology trials included assessment of PROs. However, the proportion of recent trials that supported new oncology drug approvals and assessed PROs is unknown. This review found that assessment of PROs was included in about 75% of registration trials that supported 55 new FDA drug approvals during 2014-2018. Patient-reported outcome assessment was included more in randomized controlled trials than in open-label trials (88% vs. 69%, respectively) and more in phase 3 than in phase 2 trials (89% vs. 66%, respectively).
